image: The image, inspired and adapted from Gustav Klimt's "Portrait of Adele Bloch-Bauer I", represents the mosaic patterns of focal mutation present across the brain. view more
Credit: Concept by Gilad Evrony, illustration by Erik Jacobsen of Threestory Studio
Washington, D.C. - Gilad Evrony is the 2016 grand prize winner in the annual international competition for The Eppendorf & Science Prize for Neurobiology. Evrony developed new techniques for sequencing and analyzing the genomes of individual brain cells, which revealed that diverse mutations occur during brain development, some of which may impact the brain and cause neurologic disease.
Although it was often assumed that the billions of cells in the brain have the same genome, other research suggested that the brain may harbor genetic diversity stemming from somatic mutations. Evrony was intrigued by this possibility and whether somatic mutations might drive neuropsychiatric diseases whose causes remain unknown. Together with colleagues in the laboratory of Dr. Christopher Walsh at Boston Children's Hospital, he developed a way to detect these mutations by sequencing the genomes of single brain cells.
The approach provided a first-ever detailed look at somatic mutations in the brain, and an important revelation - many types of mutations occur and accumulate during normal brain development, "such that every cell in a person's brain, in fact, has a unique genome," said Evrony, who obtained his M.D. and Ph.D. from Harvard Medical School during his time in the laboratory of Dr. Walsh. "Sequencing brain cells one at a time is challenging but necessary, because somatic mutations may be present in only a very small fraction of cells or even just one cell - making them undetectable by standard DNA sequencing." New bioinformatics methods were also needed, which Evrony developed with Eunjung Alice Lee in the laboratory of Dr. Peter Park.
The brain is built from progenitor cells that replicate many times, each time making a copy of their genome. "Our brains are a mix of cells with copies of copies, and copies of copies of copies, and so on, of the genome. Imagine you were building a house and every brick was made by copying the previous brick rather than making all the bricks from the same original mold. That is, in a sense, the challenge of building a brain where each cell must have a relatively faithful copy of the genome," Evrony states. "Inevitably, mistakes in DNA replication and other mutational forces accumulate and create imperfect copies."
Further, Evrony and colleagues were able to use the mutations they found as markers to trace how progenitor cells migrate across the brain as it is formed. This revealed interesting patterns showing that every brain is a remarkable patchwork of mosaic mutations. These technologies can now be used to study unexplained neuropsychiatric diseases, such as epilepsy, autism and schizophrenia, to determine whether somatic mutations may be involved. "As a physician-scientist, I wanted to pursue research that could help patients with diseases whose causes are not known. I hope our findings inspire more research to bring light to unsolved neurologic diseases," Evrony said.
The Eppendorf and Science Prize in Neurobiology recognizes outstanding international neurobiological research based on current methods and advances in the field of molecular and cell biology by a young, early-career scientist, as described in a 1,000-word essay based on experiments performed within the last three years. The grand prize winner receives $25,000 from Eppendorf.
In his award-winning essay, "One brain, many genomes," which will be published in the 4 November issue of Science, Evrony describes how single-cell sequencing was used to study the first brain-specific somatic mutations causing a rare congenital brain malformation known as hemimegalencephaly. The discovery provided an initial glimpse into the unexplored landscape of somatic mutations and subsequent brain dysfunction, which had been overlooked as most genetic analyses only examine the sequence of blood DNA. Because neurons and their genomes must keep working for an entire person's lifetime, this same technology could also measure how many mutations might creep into our brains as they age.
The patchwork patterns of somatic mutations that Evrony and colleagues uncovered could mean that rare, as-yet unrecognized brain disorders may exist. In these instances, a somatic mutation may subtly affect only one small part of the brain (that is involved with the ability to speak, for example), while sparing the rest of the brain. "We might be especially prone to such mutations because of the high number of cell divisions that it takes to build a large human brain," Evrony, the 15th winner of the prize suggests.
He believes these findings will ultimately paint a clearer picture of the brain's inner workings, noting, "Our work is part of the broader effort in the neuroscience community to develop new tools to study the brain. The brain is incredibly complex, and I believe that our progress in understanding it largely depends on the development of new technologies."
Evrony and the following finalists will be recognized at the annual meeting of the Society for Neuroscience on Sunday, 13 November 2016, in San Diego, California.
2016 Grand Prize Winner Gilad Evrony, for his essay "One brain, many genomes." Evrony received his undergraduate degree from the Massachusetts Institute of Technology. He served in the Intelligence Division of the Israel Defense Forces and completed an M.D. and Ph.D. at Harvard Medical School, with graduate research in Dr. Christopher Walsh's laboratory at Boston Children's Hospital. Dr. Evrony is currently pursuing clinical training in pediatrics at Mount Sinai Hospital and continuing his research developing new technologies for studying the brain and neuropsychiatric diseases.
Finalists Anna Beyeler, for her essay "Parsing reward from aversion." Beyeler received her undergraduate degree from the University of Bordeaux, in southern France, where she then completed her Ph.D. degree requirements. As a postdoctoral fellow at the Massachusetts Institute of Technology, she has been exploring the neural circuit mechanisms underlying rewarding and aversive memories. Dr. Beyeler is currently establishing an independent research program aimed at identifying neural substrates of anxiety disorders.
Arjun Krishnaswamy, for his essay "Building connections." Krishnaswamy received undergraduate and Ph.D. degrees from McGill University. As a postdoctoral fellow at Harvard University, he has been using molecular, electrophysiological, and genetic approaches to learn how developing neurons in the mouse retina choose synaptic targets and establish wiring patterns important for retinal function.
###
For the full text of finalist essays and for information about applying for next year's awards, see the Science Web site at http://www.sciencemag.org/prizes/eppendorf/2016.
About Eppendorf AG
Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid handling, sample handling, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO2 incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microliter plates, and single-use bioreactor vessels complement the range of highest-quality premium products.
Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics, and at industrial laboratories performing process analysis, production, and quality assurance.
Eppendorf was founded in Hamburg, Germany in 1945 and has about 3,000 employees worldwide. The company has subsidiaries in 25 countries and is represented in all other markets by distributors.
About AAAS
The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society and publisher of the journal Science as well as Science Translational Medicine, Science Signaling, a digital, open-access journal, Science Advances, Science Immunology, and - coming soon - Science Robotics. AAAS was founded in 1848 and includes nearly 250 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world. The non-profit AAAS is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy, international programs, science education, public engagement, and more. For the latest research news, log onto EurekAlert!, the premier science-news Web site, a service of AAAS. See http://www.aaas.org.